<DOC>
	<DOCNO>NCT01046903</DOCNO>
	<brief_summary>The objective study observe safety , tolerability , compliance use Fragmin® prolong thromboprophylaxis post-surgery high-risk orthopedic patient .</brief_summary>
	<brief_title>An Observational Study On The Safety And Tolerability Of Prolonged Thrombosis Prophylaxis With Fragmin®</brief_title>
	<detailed_description>All patient prescribe Fragmin® ( Dalteparin Sodium ) prolong thromboprophylaxis eligible study</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Male female patient , undergo major orthopedic surgery At least 18 year old Hypersensitivity Fragmin low molecular weight heparin unfractioned heparin ; History heparin induce thrombocytopaenia type II Acute gastroduodenal ulcer , cerebral haemorrhage , active haemorrhage . Serious coagulation disorder ; Septic endocarditis ; Injuries operation central nervous system , eye ear within one month orthopaedic surgery ; Spinal epidural anesthesia procedure require spinal puncture concomitant treatment high dos dalteparin ( need treat acute deep vein thrombosis , pulmonary embolism , Unstable coronary artery disease ) ; Patients serum creatinine level &gt; 150 umol/l ; Platelet count less 100 000 per cubic millimeter begin therapy ; High probability patient return centre followup ; Patient oral anticoagulation therapy last 7 day ; Ongoing anticoagulant therapy medication nonpharmacologic therapy study period ; Weight le 40 kg ; Simultaneous participation another pharmacological study receive investigational drug 30 day less surgery ; Pregnancy breastfeeding ; Clinically significant hepatic dysfunction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>observational prolong thromboprophylaxis</keyword>
</DOC>